Enhanced patient support services improve patient persistence with multiple sclerosis treatment

BACKGROUND: Subcutaneous interferon beta-1a (sc IFN β-1a) therapy (44 µg or 22 µg, three times weekly) improves relapse rates and disability progression in patients with relapsing multiple sclerosis (MS). While early treatment with disease-modifying drugs may maximize therapeutic benefit, patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Jane, McCarry, Yvonne, Mellors, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062553/
https://www.ncbi.nlm.nih.gov/pubmed/24966668
http://dx.doi.org/10.2147/PPA.S59496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062553/
https://www.ncbi.nlm.nih.gov/pubmed/24966668
http://dx.doi.org/10.2147/PPA.S59496

Ejemplares similares